Filtered By:
Condition: Heart Failure
Nutrition: Calcium

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 213 results found since Jan 2013.

Effects of Blood Pressure Lowering Agents on Cardiovascular Outcomes in Weight Excess Patients: A Systematic Review and Meta-analysis
ConclusionsIn hypertensive subjects with excess weight, diuretics are more effective for preventing HF and stroke than CCB and ACEI, respectively. CCB are a good first-line choice for prevention of cardiovascular disease, except HF.
Source: American Journal of Cardiovascular Drugs - January 2, 2020 Category: Cardiology Source Type: research

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Results by Sex Clinical Trial - ALLHAT
To determine whether an angiotensin-converting enzyme inhibitor (lisinopril) or calcium channel blocker (amlodipine) is superior to a diuretic (chlorthalidone) in reducing cardiovascular disease incidence in sex subgroups, we carried out a prespecified subgroup analysis of 15 638 women and 17 719 men in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Total follow-up (active treatment + passive surveillance using national administrative databases to ascertain deaths and hospitalizations) was 8 to 13 years. The primary outcome was fatal coronary heart disease or nonfatal myocardial i...
Source: Hypertension - April 17, 2013 Category: Cardiology Authors: Oparil, S., Davis, B. R., Cushman, W. C., Ford, C. E., Furberg, C. D., Habib, G. B., Haywood, L. J., Margolis, K., Probstfield, J. L., Whelton, P. K., Wright, J. T., for the ALLHAT Collaborative Research Group Tags: Primary prevention, Secondary prevention, Clinical Studies Clinical Trial - ALLHAT Source Type: research

Current Approaches to the Treatment of Hypertension in Older Persons
Wilbert S. Aronow, MD, FACC, FAHA DOI: 10.3810/pgm.2012.01.2517 Abstract: Hypertension is a major risk factor for cardiovascular disease and is present in 69% of patients with a first myocardial infarction, in 77% of patients with a first stroke, in 74% of patients with chronic heart failure, and in 60% of patients with peripheral arterial disease. Double-blind, randomized, placebo-controlled trials have demonstrated that antihypertensive drug therapy reduces cardiovascular events in patients aged 65 to 79 years. In the Hypertension in the Very Elderly Trial, patients aged ≥ 80 years who were treated with antihype...
Source: Postgraduate Medicine Online - February 3, 2012 Category: Internal Medicine Authors: admin Source Type: research

Antihypertensive treatment and risk of atrial fibrillation: a nationwide study
Conclusion Use of ACEis and ARBs compared with β-blockers and diuretics associates with a reduced risk of atrial fibrillation, but not stroke, within the limitations of a retrospective study reporting associations. This suggests that controlling activation of the renin-angiotensin system in addition to controlling blood pressure is associated with a reduced risk of atrial fibrillation.
Source: European Heart Journal - May 7, 2014 Category: Cardiology Authors: Marott, S. C. W., Nielsen, S. F., Benn, M., Nordestgaard, B. G. Tags: Hypertension Source Type: research

Fibroblast Growth Factor-23 and Cardiovascular Disease in the General Population: The Multi-Ethnic Study of Atherosclerosis Original Articles
Conclusions— Higher serum FGF-23 concentrations are associated with subclinical cardiac disease and with new heart failure and coronary disease events, but not with carotid intima-media thickness or stroke. FGF-23 may be a novel cardiovascular risk factor in the general population.
Source: Circulation: Heart Failure - May 20, 2014 Category: Cardiology Authors: Kestenbaum, B., Sachs, M. C., Hoofnagle, A. N., Siscovick, D. S., Ix, J. H., Robinson-Cohen, C., Lima, J. A. C., Polak, J. F., Blondon, M., Ruzinski, J., Rock, D., de Boer, I. H. Tags: Congestive, Epidemiology Original Articles Source Type: research

Calcium Channel Blocker Compared With Angiotensin Receptor Blocker for Patients With Hypertension: A Meta‐Analysis of Randomized Controlled Trials
To explore the clinical effects of a calcium channel blocker compared with an angiotensin II receptor blocker in hypertensive patients, the authors collected data from randomized controlled trials. The pooled outcomes were all‐cause mortality, stroke, myocardial infarction, and heart failure. Eight head‐to‐head trials enrolling 25,084 patients were included. There was no significant mortality difference in the two arms (relative risk, 0.99; 95% confidence interval, 0.91–1.07). However, calcium channel blockers were more effective in reducing stroke (relative risk, 0.87; 95% confidence interval, 0.76–0.99) and myo...
Source: The Journal of Clinical Hypertension - July 1, 2014 Category: Cardiology Authors: Ling Wu, Song‐Bai Deng, Qiang She Tags: Review Paper Source Type: research

Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses
Conclusions: The results of all available evidence from head-to-head drug class comparisons do not allow the formulation of a fixed paradigm of drug choice valuable for all hypertensive patients, but the differences found may suggest specific choices in specific conditions, or preferable combinations of drugs.
Source: Journal of Hypertension - June 5, 2015 Category: Cardiology Tags: Reviews Source Type: research

Association of Thoracic Aorta Calcium Score With Exercise Blood Pressure Response and Clinical Outcomes in Elderly Individuals: Differential Impact of Aorta Calcification Compared With Coronary Artery Calcification Preventive Cardiology
Conclusions Aortic calcification was related to SBP response during exercise and was an independent predictor for outcomes, especially stroke, regardless of resting SBP or CACS.
Source: JAHA:Journal of the American Heart Association - April 21, 2016 Category: Cardiology Authors: Cho, I.-J., Chang, H.-J., Cho, I., Heo, R., Lee, S.-E., Shim, C. Y., Hong, G.-R., Chung, N. Tags: Computerized Tomography (CT) Preventive Cardiology Source Type: research

Efficacy of Calcium Channel Blockers on Major Cardiovascular Outcomes for the Treatment of Hypertension in Asian Populations: A Meta Analysis
Conclusion There is no evidence that dihydropyridine calcium channel blockers are superior to other antihypertensive agents in Asian populations for the treatment of hypertension. Teaser Whether calcium channel blockers exert a greater effect on cardiovascular risk reduction in Asian populations than other antihypertensive agents is unknown. We conducted a meta-analysis of hypertension trials of dihydropyridine calcium channel blockers in Asian populations to clarify this association. We noted no evidence that dihydropyridine calcium channel blockers are superior to other antihypertensive agents in Asian populations at red...
Source: Canadian Journal of Cardiology - January 20, 2017 Category: Cardiology Source Type: research

Association of anti-hyperuricemia treatment and prevalent cardiovascular disease in hypertensive patients.
Conclusions: In hypertensive patients with hyperuricemia, anti-hyperuricemia treatment was associated with lower odds of prevalent CVD. PMID: 32399101 [PubMed]
Source: Archives of Medical Science - May 15, 2020 Category: General Medicine Tags: Arch Med Sci Source Type: research

Calcium channel blockers versus other classes of drugs for hypertension
CONCLUSIONS: For the treatment of hypertension, there is moderate certainty evidence that diuretics reduce major cardiovascular events and congestive heart failure more than CCBs. There is low to moderate certainty evidence that CCBs probably reduce major cardiovascular events more than beta-blockers. There is low to moderate certainty evidence that CCBs reduced stroke when compared to angiotensin-converting enzyme (ACE) inhibitors and reduced myocardial infarction when compared to angiotensin receptor blockers (ARBs), but increased congestive heart failure when compared to ACE inhibitors and ARBs. Many of the differences ...
Source: Cochrane Database of Systematic Reviews - October 17, 2021 Category: General Medicine Authors: Jiaying Zhu Ning Chen Muke Zhou Jian Guo Cairong Zhu Jie Zhou Mengmeng Ma Li He Source Type: research

Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis
Conclusion The presence of resistant hypertension identifies a subgroup of patients with hypertension and atherothrombosis who are at heightened risk for adverse long-term outcomes.
Source: European Heart Journal - April 21, 2013 Category: Cardiology Authors: Kumbhani, D. J., Steg, P. G., Cannon, C. P., Eagle, K. A., Smith, S. C., Crowley, K., Goto, S., Ohman, E. M., Bakris, G. L., Perlstein, T. S., Kinlay, S., Bhatt, D. L., on Behalf of the REACH Registry Investigators Tags: Hypertension Source Type: research

Inotropic and Lusitropic Effects of Calcitonin Gene-Related Peptide in the Heart.
Abstract Previous studies have demonstrated positive-inotropic effects of calcitonin gene-related peptide (CGRP) but the mechanisms remain unclear. Therefore, two experiments were performed to determine the physiological correlates of the positive-inotropic effects of CGRP. Treatments designed to antagonize the effects of physiologically-active CGRP 1-37 included post-treatment with CGRP8-37 and pretreatment with LY294002 (LY, an inhibitor of PI3K), 17β-estradiol (E) and progesterone (P) were also used to modulate the effects of CGRP1-37. Experiment 1: In vitro studies on sarcomeres and cells of isolated adult ra...
Source: American Journal of Physiology. Heart and Circulatory Physiology - April 12, 2013 Category: Physiology Authors: Al-Rubaiee M, Gangula PR, Millis RM, Walker RK, Umoh NA, Cousins VM, Jeffress MA, Haddad GE Tags: Am J Physiol Heart Circ Physiol Source Type: research